Injectable botulinum toxin formulations
AssigneeRevance Therapeutics, Inc.
InventorsCurtis L. Ruegg, Hongran Fan Stone, Jacob M. Waugh
Life of this patent
Estimating the term…
Abstract
This invention provides novel injectable compositions comprising botulinum toxin that may be administered to a subject for various therapeutic, aesthetic and/or cosmetic purposes. The injectable compositions contemplated by the invention exhibit one or more advantages over conventional botulinum toxin formulations, including reduced antigenicity, a reduced tendency to undergo unwanted localized diffusion following injection, increased duration of clinical efficacy or enhanced potency relative, faster onset of clinical efficacy, and/or improved stability.
Claims49
A method of administering botulinum toxin to achieve a therapeutic or cosmetic effect to an individual, the method comprising
- injecting an effective amount of a sterile injectable composition into the individual at an area in need of treatment to achieve a therapeutic or cosmetic effect,
- wherein the composition comprises
- a positively charged carrier comprising the amino acid sequence RKKRRQRRRG-(K)15-GRKKRRQRRR (SEQ ID NO:
- 7),
- a botulinum toxin component present in an amount suitable for injection, the botulinum toxin component selected from the group consisting of a botulinum toxin complex, reduced botulinum toxin complex, and botulinum toxin, and
- a pharmaceutically acceptable diluent suitable for injection;
- wherein the positively charged carrier is non-covalently associated with the botulinum toxin component.
A method of administering botulinum toxin to reduce or prevent a muscle spasm in a subject, the method comprising injecting an effective amount of a sterile injectable composition into the subject at an area affected by muscle spasm, wherein the composition comprises a positively charged carrier comprising the amino acid sequence RKKRRQRRRG-(K)15-GRKKRRQRRR (SEQ ID NO:
- 7), a botulinum toxin component present in an amount suitable for injection, the botulinum toxin component selected from the group consisting of a botulinum toxin complex, reduced botulinum toxin complex, and botulinum toxin, and a pharmaceutically acceptable diluent suitable for injection;
- wherein the positively charged carrier is non-covalently associated with the botulinum toxin component.
Dependencies are inferred from the claim text.